Clinical Report: Copper Oxide Nanoparticles and EU Regulations

Overview

This review examines the regulatory framework for copper oxide nanoparticles (CuO and Cu2O) in the EU, highlighting potential health hazards and the need for differentiated regulations for nanoforms. It emphasizes the unique biological interactions and toxicity mechanisms associated with these nanoparticles, particularly in relation to cuproptosis.

Background

Copper is an essential trace element, but its nanoparticle forms raise concerns regarding toxicity and health risks. Current EU regulations do not adequately differentiate between nanoforms and non-nanoforms, potentially leading to unintentional exposure through food and feed. Understanding the biological interactions and regulatory gaps is crucial for ensuring safety in the use of copper nanoparticles.

Data Highlights

No numerical data or trial data presented in the article.

Key Findings

• CuO and Cu2O nanoparticles are permitted in the EU for various applications, but regulations do not uniformly address their nanoform.
• Potential health hazards from CuO and Cu2O nanoparticles are influenced by their biological interactions, differing from ionic copper.
• There is a need for regulatory frameworks to consider the unique properties and risks of nanoparticles.
• CuO and Cu2O nanoparticles may traverse the intestinal barrier and accumulate in vulnerable tissues.
• These nanoparticles can initiate biological responses distinct from those of ionic copper, including pathways of regulated cell death like cuproptosis.

Clinical Implications

Healthcare professionals should be aware of the potential risks associated with copper oxide nanoparticles, particularly in food and feed applications. The regulatory landscape may require updates to ensure adequate safety assessments for these nanoforms.

Conclusion

The review highlights significant regulatory gaps regarding copper oxide nanoparticles and underscores the importance of understanding their unique biological effects to inform future safety assessments.

Related Resources & Content

1. Sajjad et al., Archives of Toxicology, 2023 -- Modification of CuO Nanoparticles through Surface Carboxylation or PEGylation Reduces Cytotoxic Effects on Human Cells In Vitro While Preserving Antibacterial Activity
2. Archives of Toxicology, 2025 -- Applicability of in vitro mouse lung epithelial cell responses for potency grouping and hazard identification of metal oxide nanoparticles: impact of form, size, surface area, and solubility on toxicity
3. Archives of Toxicology, 2024 -- Mechanisms of Neurotoxicity Induced by Copper in Differentiated Human Neurons
4. COMMISSION IMPLEMENTING REGULATION (EU) 2018/1981 - renewing the approval of the active substances copper compounds
5. Archives of Toxicology — The use of new approach methodologies (high-throughput transcriptomics) to study nanoagrochemicals: mechanisms of toxicity of a commercial copper oxychloride to soil model invertebrates (Enchytraeus crypticus)
6. Guidance on Sample Preparation and Dosimetry for Manufactured Nanomaterials, 2025 Edition
7. Copper oxide nanoparticles induce pulmonary inflammation via triggering cellular cuproptosis
8. COMMISSION IMPLEMENTING REGULATION (EU) 2018/ 1981 - of 13 December 2018 - renewing the approval of the active substances copper compounds, as candidates for substitution, in accordance with Regulation (EC) No 1107 / 2009 of the European Parliament and of the Council concerning the placing of plant protection products on the market, and amending the Annex to Commission Implementing Regulation (EU) No 540 / 2011